What is the recommended treatment protocol for an adult presenting with a generalized tonic‑clonic seizure, including acute management and long‑term seizure prophylaxis?

Treatment Protocol for Generalized Tonic-Clonic Seizures (GTCS)

Acute Management in the Emergency Department

For benzodiazepine-refractory status epilepticus, administer fosphenytoin, levetiracetam, or valproate as second-line agents—all three demonstrate similar efficacy in terminating seizures. 1

First-Line Treatment

• Administer benzodiazepines immediately for ongoing seizure activity 1, 2
• Lorazepam is preferred over other benzodiazepines due to longer-acting central nervous system effects 3
• Benzodiazepines alone achieve seizure cessation in 54-84% of cases 2

Second-Line Treatment (Benzodiazepine-Refractory)

When seizures continue despite optimal benzodiazepine dosing, the 2024 ACEP guidelines establish Level A evidence for three equally effective options 1:

• Levetiracetam: Life-threatening hypotension in only 0.7%, cardiac arrhythmias in 0.7%, intubation required in 20% 1
• Fosphenytoin: Life-threatening hypotension in 3.2%, intubation required in 26.4% 1
• Valproate: Life-threatening hypotension in 1.6%, intubation required in approximately 20-26% 1

Levetiracetam demonstrates the most favorable safety profile with lowest rates of hypotension and cardiac complications 1

Refractory Status Epilepticus

• If seizures persist beyond 60 minutes despite first and second-line agents, initiate general anesthesia with respiratory support 4, 2
• Options include midazolam, propofol, or barbiturate coma with thiopental/pentobarbital 2, 3

---

Long-Term Seizure Prophylaxis

First-Line Antiseizure Medications

Valproic acid remains the first-choice agent for males and postmenopausal women with primary GTCS, while lamotrigine and levetiracetam serve as first-line alternatives for women of childbearing potential. 5

Evidence-Based First-Line Options:

• Valproic acid: Most effective for primary GTCS in appropriate populations (males, postmenopausal women) 5, 6

  • Significantly reduces risk of experiencing GTCS (OR: 0.58) 6
  • Contraindicated in women of childbearing age due to teratogenicity and cognitive concerns 5

• Lamotrigine: Class 1 evidence for primary GTCS efficacy 7

  • Viable first-line alternative, particularly for women of childbearing potential 5
  • Supported by regulatory data for both primary and secondary GTCS 7

• Levetiracetam: Class 1 evidence for primary GTCS 7

  • Excellent safety profile with minimal drug interactions 7
  • Effective first-line option across all patient populations 5

• Topiramate: Class 1 evidence for primary GTCS 7

  • Effective but concerns exist regarding cognitive and memory adverse effects 5

Second-Line Options:

• Perampanel: Class 1 evidence for primary GTCS, promising for refractory cases 7, 5
• Lacosamide: Emerging evidence supports use, particularly for focal to bilateral tonic-clonic seizures 5, 8

Treatment Response Expectations

• Median time to achieve 2-year remission: 24 months with median of 1 antiseizure medication 9
• Drug resistance occurs in only 16.3% of GTCA patients 9
• Early treatment response is common: 34.3% achieve early remission pattern 9
• Untreated patients experience 73% recurrence rate versus 14% in treated patients 10

Medication Withdrawal Considerations

• Attempt withdrawal only after minimum 2-3 years of seizure freedom 10, 9
• Physician-supervised tapering significantly reduces recurrence risk compared to patient-initiated discontinuation 10
• Seizure recurrence after withdrawal occurs in 44-83% of patients 10, 9
• Longer duration of seizure freedom predicts successful withdrawal 9
• Absence of generalized spike-wave discharges on EEG improves withdrawal success 10

Common Pitfalls to Avoid

• Do not withhold valproate from women with IGE after first-line failure without careful risk-benefit discussion—this may not serve the patient's best interests given valproate's superior efficacy 6
• Avoid premature medication withdrawal before 2 years of seizure freedom 10, 9
• Monitor for catamenial seizures and morning GTCS predominance, which independently predict drug resistance 9
• Emphasize lifestyle modifications and seizure precautions, as 36.3% of patients display relapsing-remitting patterns despite treatment 9